Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities (2022 - 2025)

Stoke Therapeutics has reported Cash from Financing Activities over the past 4 years, most recently at $92.3 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $92.3 million for Q4 2025, up 16157.22% from a year ago — trailing twelve months through Dec 2025 was $97.4 million (down 25.71% YoY), and the annual figure for FY2025 was $97.4 million, down 25.71%.
  • Cash from Financing Activities for Q4 2025 was $92.3 million at Stoke Therapeutics, up from $3.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for STOK hit a ceiling of $120.6 million in Q2 2024 and a floor of $43000.0 in Q4 2022.
  • Median Cash from Financing Activities over the past 4 years was $2.4 million (2024), compared with a mean of $20.5 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 251254.17% in 2024 and later crashed 99.54% in 2025.
  • Stoke Therapeutics' Cash from Financing Activities stood at $43000.0 in 2022, then skyrocketed by 16976.74% to $7.3 million in 2023, then plummeted by 92.26% to $568000.0 in 2024, then skyrocketed by 16157.22% to $92.3 million in 2025.
  • The last three reported values for Cash from Financing Activities were $92.3 million (Q4 2025), $3.1 million (Q3 2025), and $554000.0 (Q2 2025) per Business Quant data.